Inflammation, Epigenetics in CHF Patients With AF

Completed

• Conditions: Congestive Heart Failure Chronic; Atrial Fibrillation (Permanent)

• Registration Number: NCT07152301
• Lead Sponsor: University of Palermo

Brief Summary

the goal of this case-control cross-sectional study is assessing in a cohort of patients with CHF and permanent AF

* The serum levels of some candidate cytokine variables and their relationship with some selected metabolic variables and some echocardiographic variables.

* the expression degree of some selected miRNA with a pathogenetic relation to atrial fibrillation and the related cardiac remodelling.

* to analyze the correlation between selected miRNA and the selected cytokines.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-01-01
• Primary Completion: 2022-05-31
• Study Completion: 2022-05-31
• Study First Submitted: 2025-08-16
• Study First Submitted QC: 2025-08-25
• Status Verified: 2025-09
• Study First Posted: 2025-09-03
• Last Update Submitted: 2025-09-03
• Last Update Posted: 2025-09-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 164

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
inflammation and structural cardiac remodelling	From January 2020 to May 2022	in both arms of the study (AF + CHF and CHF no AF) a blood sample will be performed for the determination of serum values of inflammatory cytokines (CRP in mg/l; IL6 in pg/ml) and a transthoracic echocardiogram for the evaluation of the left atrial volume index in ml/m2 and the left atrial strain %

Secondary Outcome Measures

Name	Time	Method
epigenetic alterations and cardiac remodelling	From January 2020 to May 2022	in both arms of the study (AF + CHF and CHF no AF) a blood sample will be performed for the determination of the expression degree of some selected miRNA with a pathogenetic relation to atrial fibrillation (hsa-miR-1-3p, hsa-miR-26a-5p, hsa-miR-21-5p in nmol/l), and a transthoracic echocardiogram for the evaluation of the left atrial volume index in ml/m2 and the left atrial strain %
inflammation and epigenetic alterations	From January 2020 to May 2022	in both arms of the study (AF + CHF and CHF no AF) a blood sample will be performed for the determination of the expression degree of some selected miRNA with a pathogenetic relation to atrial fibrillation (hsa-miR-1-3p, hsa-miR-26a-5p, hsa-miR-21-5p in nmol/l), and a blood sample for the determination of serum values of inflammatory cytokines (CRP in mg/l; IL6 in pg/ml)

Trial Locations

Locations (1)

Internal Medicine and Stroke Care Ward, Policlinic Hospital of Palermo, Sicily; 🇮🇹 Palermo, PA, Italy